1-[(4-Chlorophenyl)methyl]-6-(3-fluoroanilino)-3-(2-hydroxyethyl)-1,3,5-triazine-2,4-dione | 1239688-40-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 1-[(4-Chlorophenyl)methyl]-6-(3-fluoroanilino)-3-(2-hydroxyethyl)-1,3,5-triazine-2,4-dione
• CAS: 1239688-40-4
• 化学式: C₁₈H₁₆ClFN₄O₃
• 分子量: 390.801
• InChiKey: QIBNYGIZKWHAFD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  85.2
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOUND THAT CONTAINS SAME AND EXHIBITS ANALGESIC ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：EP2604595A1

  公开（公告）日：2013-06-19

  The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect. A pharmaceutical composition having an analgesic effect or an improving effect of urination disorder comprising a compound of the formula (I): wherein Rh and Rj are taken together to form a bond; Ra and Rb and/or Rd and Re are taken together to form oxo or the like; Rc is hydrogen, substituted or unsubstituted alkyl or the like; Rf is -(CR4aR4b)n-R2; R4a and R4b are hydrogen, substituted or unsubstituted alkyl or the like; R2 is substituted or unsubstituted cycloalkyl or the like; n is an integer of 1 to 4; -Rg is -X-R3; -X- is -O-, -S- or the like; R3 is substituted or unsubstituted cycloalkyl or the like, or its pharmaceutically acceptable salt or a solvate thereof.

  本发明提供了具有 P2X3 和/或 P2X2/3 受体拮抗作用的新型化合物。 一种具有镇痛效果或改善排尿障碍效果的药物组合物，由式（I）化合物组成： 其中 Rh 和 Rj 共同形成键；Ra 和 Rb 和/或 Rd 和 Re 共同形成氧代或类似物；Rc 是氢、取代或未取代的烷基或类似物； Rf是-(CR4aR4b)n-R2；R4a和R4b是氢、取代或未取代的烷基或类似物；R2是取代或未取代的环烷基或类似物；n是1至4的整数；-Rg是-X-R3；-X-是-O-、-S-或类似物；R3是取代或未取代的环烷基或类似物、 或其药学上可接受的盐或其溶液。
• EP2604595B1
  申请人：——

  公开号：EP2604595B1

  公开（公告）日：2016-03-16
• NOVEL TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：Kai Hiroyuki

  公开号：US20110319414A1

  公开（公告）日：2011-12-29

  The present invention provides a novel P2X 3 and/or P2X 2/3 receptor antagonist. A compound represented by the formula (I); wherein R a , R b and R c are, (a) R a and R b are taken together ═Z; and R c is a group represented by R 1c ; or (b) R b and R c are taken together to form a bond; and R a is a group represented by —Y—R 1a ; R 1a and R 1c are each independently hydrogen, substituted or unsubstituted alkyl, etc.; R 2 and R 3 are each independently substituted or unsubstituted aryl, etc.; R 4a and R 4b are each independently hydrogen, substituted or unsubstituted alkyl, etc.; X is —N(R 5 )—, etc.; R 5 is hydrogen, substituted or unsubstituted lower alkyl, etc.; —Y— is —O—, etc.; ═Z is ═O, etc.; and n is an integer of 0 to 4.
• NOVEL, TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：Shionogi & Co., Ltd.

  公开号：US20160185736A1

  公开（公告）日：2016-06-30

  The present invention provides a novel P2X 3 and/or P2X 2/3 receptor antagonist. A compound represented by the formula (I): wherein R a , R b and R c are, (a) R a and R b are taken together ═Z; and R c is a group represented by R 1c ; or (b) R b and R c are taken together to form a bond; and R a is a group represented by —Y—R 1a ; R 1a and R 1c are each independently hydrogen, substituted or unsubstituted alkyl, etc.; R 2 and R 3 are each independently substituted or unsubstituted aryl, etc.; R 4a and R 4b are each independently hydrogen, substituted or unsubstituted alkyl, etc.; X is —N(R 5 )—, etc.; R 5 is hydrogen, substituted or unsubstituted lower alkyl, etc.; —Y— is —O—, etc.; ═Z is ═O, etc.; and n is an integer of 0 to 4.
• US9150546B2
  申请人：——

  公开号：US9150546B2

  公开（公告）日：2015-10-06